BRAF and non-small cell lung carcinoma: For example, non-small cell lung cancer (NSCLC) regimens are organized by EGFR, ALK, BRAF, and ROS1 mutation status; kinase inhibitors are categorized by their target kinase(s) and biomarker-specific FDA labeling is noted.